Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07565493 · ClinicalTrials.gov registry record · Early Phase 1
Psilocybin Administration With 5-HT1a Blockade
A Early Phase 1 study, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT07565493: Recruiting Early Phase 1 study, sponsored by Johns Hopkins University.
NCT07565493 is a Early Phase 1 study that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07565493, a Early Phase 1 study, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG). Further, the investigators will assess the effects of psilocybin on post-acute sleep and dreaming through the use of sleep EEG and sleep and dream diaries.
Interventions
- DRUG Placebo
- DRUG Psilocybin
- DRUG Pindolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2028-06-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07565493
The ClinicalTrials.gov registry entry for NCT07565493 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07565493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07565493 about?
NCT07565493 is a clinical study titled "Psilocybin Administration With 5-HT1a Blockade". The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG). Further, the investigators will assess the effects of psilocybin on post-acute sleep an...
What is the current status of trial NCT07565493?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2026-08-01. Estimated completion is 2028-06-15.
What interventions are being tested in trial NCT07565493?
The interventions under investigation include: Placebo (DRUG), Psilocybin (DRUG), Pindolol (DRUG).
Who is sponsoring clinical trial NCT07565493?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.